FDA loosens restrictions on naloxone distribution

The FDA is loosening requirements surrounding the distribution of naloxone to increase Americans’ access to the opioid overdose antidote.

Advertisement

The FDA will not enforce certain Drug Supply Chain Security Act requirements for public health programs that distribute naloxone to underserved communities while the opioid public health emergency declaration is in effect, the agency said in guidance released Sept. 22.

The guidance comes about five months after President Joe Biden shared a formal plan with Congress to address the nation’s addiction and drug overdose crisis, part of which called for increasing access to naloxone.    

View the FDA’s full guidance here.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.